Newbury Pharmaceuticals
Courtagefri handel på Nordnet till sista juni 2027! Har du inget konto på Nordnet så är det verkligen läge att skaffa ett. Just nu får nya kunder courtagefri handel till sista juni 2027. Läs mer om erbjudandet och skapa ditt konto här Erbjudandet gäller nya kunder och omfattar handel via Nordnets app eller hemsida i nordiska aktier, ETF:er, teckningsrätter och teckningsoptioner. För fullständiga villkor se nordnet.se/jubileum. Kom ihåg att investeringar alltid innebär en risk.
Newbury Pharmaceuticals has entered into a new partnership for Prucalopride tablets
Newbury has signed a contract with a new partner to register and launch Prucalopride in Sweden. Prucalopride, 1 and 2 mg tablets, is a selective, high affinity 5-HT4 receptor agonist which targets the impaired motility associated with chronic constipation, thus normalizing bowel movements.
“With the addition of prucalopride, we have established a strategic partnership with a multinational pharmaceutical company recognized for its advanced R&D capabilities, global regulatory approvals, and presence across major healthcare markets worldwide. This collaboration not only strengthens our portfolio today but also provides a basis for bringing additional products to market in the future, supporting our ambition to become the local champion and partner of choice,” says Mr. Karl Karlsson, CEO of Newbury.
Regulatory approval is expected in the near future, with a planned launch in Sweden later this year.
| Datum | 2026-03-18, kl 16:45 |
| Källa | MFN |